近日，在洛杉矶举行的2024年美国感染性疾病周（IDWeek）会议期间，默沙东和辉瑞分别展示了其针对呼吸道合胞病毒（RSV）的预防药物新数据，并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会，每年吸引 ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

▎药明康德内容团队编辑日前，辉瑞（Pfizer）宣布美国FDA已批准其呼吸道合胞病毒（RSV）疫苗Abrysvo（RSVpreF），用于预防18至59岁高风险个体因RSV引起的下呼吸道疾病（LRTD）。此前，该疫苗已获批用于60岁及以上的成人群体。根 ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

纽约 - 辉瑞制药公司（NYSE: ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...